A c c e p t e d M a n u s c r i p Gram-negative isolates were tested against amikacin, AMC, ampicillin, cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, meropenem, minocycline, TZP and tigecycline. As a result of stability issues, imipenem was replaced by meropenem in 2006; MicroScan ® panels were replaced by Sensititre ® plates that same year. MIC determinations were carried out using cation-adjusted
Mueller-Hinton broth (Streptococcus spp. were cultured in Mueller-Hinton broth supplemented with lysed horse blood). In 2008, the test panel for S. pneumoniae was extended to include azithromycin, clarithromycin, clindamycin and erythromycin; this means that some isolates were tested retrospectively.
Laboratories International for Microbiology Studies, a division of International Health Management Associates, Inc. (IHMA, Schaumburg, IL), was responsible for isolate collection and transport as well as the management of a centralised T.E.S.T. database; IHMA's role in T.E.S.T. has been described in detail elsewhere [6] .
Antimicrobial susceptibility was determined using interpretive criteria as described by the CLSI [7] ; non-meningeal oral breakpoints have been applied to S. pneumoniae. US Food and Drug Administration (FDA)-approved breakpoints were used for tigecycline, as provided in the tigecycline package insert [3] . Statistically significant changes in susceptibility were identified using the Cochran-Armitage test for trend.
A c c e p t e d M a n u s c r i p 10 MIC 90 (MIC required to inhibit 90% of the isolates) (2 mg/L) was recorded for A. baumannii. Overall susceptibility was low in Pakistan (Table 2) .
Among non-A. baumannii Acinetobacter spp. (n = 33), 84.8% and 66.7% of isolates were susceptible to minocycline and meropenem, respectively; an MIC 90 of 1 mg/L for tigecycline to non-A. baumannii was observed.
Haemophilus influenzae (n = 605) were highly susceptible (≥97.9%) to most agents on the T.E.S.T. panel (Table 2a ). β-Lactamase-positive H.
influenzae were rare in most countries (<10 in Jordan, Lebanon, Mauritius, Oman, Pakistan and Saudi Arabia).
Changes in susceptibility
Significant (P < 0.01) changes in susceptibility were examined only in Israel and South Africa owing to insufficient isolate numbers from other countries. In Israel, significant decreases in minocycline susceptibility were noted among A. baumannii A c c e p t e d M a n u s c r i p 
Discussion
Staphylococcus aureus and enterococci susceptibility rates resemble reports from other recent studies. Staphylococcus aureus susceptibility to tigecycline, linezolid and vancomycin was 100% in the current study. These results corroborate findings in a recent report from Lebanon [8] , although vancomycin-resistant S. aureus isolates have been reported in the region [9] . Salem-Bekhit et al. [10] [4] .
Acinetobacter baumannii isolates were 7-17% less susceptible to cefepime, ceftazidime, meropenem and TZP compared with the 2004-2011 interval, likely due in part to the 2004-2009 data containing only ICU isolates, which are generally more resistant than non-ICU isolates. These changes may also be due to changes in participating centres that occur in surveillance studies.
Although not indicated for the treatment of infections caused by Acinetobacter spp., tigecycline is often regarded as a viable treatment option for multidrug-resistant Acinetobacter infections [11] . The Enterobacteriaceae susceptibility breakpoint (≤2 mg/L) is often used for tigecycline in the M a n u s c r i p 12 absence of CLSI tigecycline susceptibility breakpoints. An MIC 90 of 2 mg/L was recorded for tigecycline against Acinetobacter in the current study. Low tigecycline resistance in Lebanon (0% resistant, 2% intermediate) and Kuwait (13.6% resistant) reflected good activity against
Acinetobacter reported in the current study [8, 12] .
Previous studies have reported 100% tigecycline susceptibility among E. coli isolates from Lebanon and Oman, including ESBL-producers [12, 13] . Only one single (0.1%) non-susceptible E. coli isolate from Jordan was reported in the current study. No E. coli ESBL production was observed from Lebanon, possibly due to sampling error: in comparison, another recent study demonstrated ESBL production among E. coli of 30% in a tertiary care centre in Lebanon in 2011 [8] . Two imipenem-non-susceptible isolates of K. pneumoniae were collected in the current study, one of which was resistant to tigecycline. (AcrAB), Providencia spp., P. aeruginosa (MexXY-OprM) and Salmonella enterica] to reduce susceptibility to tigecycline. Efflux pumps are also responsible for tigecycline resistance among Burkholderia spp., whilst overexpression of multidrug and toxin extrusion (MATE) family efflux pumps (MepA) may reduce tigecycline susceptibility among S. aureus isolates. Although still uncommon, resistance to those agents commonly used against multidrug-resistant pathogens, such as tigecycline and colistin, has occurred in some regions [11] . Molecular resistance mechanisms are not identified as part of T.E.S.T.
Tigecycline retains in vitro activity against a wide range of organisms collected from the Middle East and Africa. The results presented highlight the importance of newer antimicrobial agents such as tigecycline, which do not share cross-resistance with other commonly used antibacterial drugs [3] . The question of whether the in vitro activity of tigecycline corresponds to clinical efficacy is unclear. Tigecycline may offer an addition to the limited armamentarium available for the management of infections caused by increasingly resistant pathogens.
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Mauritius 11
A c c e p t e d M a n u s c r i p -(n = 9)
Namibia 5 - 
A c c e p t e d M a n u s c r i p 25 Mauritius 6 -
A c c e p t e d M a n u s c r i p Mauritius 7 -
Pakistan 33 ≥128 63. A c c e p t e d M a n u s c r i p 
Pakistan 24 ≥128 83. 
